Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;37(1):62-74.
doi: 10.1177/8755122520967634. Epub 2020 Oct 30.

Remdesivir and Coronavirus Disease 2019 (COVID-19): Essential Questions and Answers for Pharmacists and Pharmacy Technicians

Affiliations
Review

Remdesivir and Coronavirus Disease 2019 (COVID-19): Essential Questions and Answers for Pharmacists and Pharmacy Technicians

Michael A Veronin et al. J Pharm Technol. 2021 Feb.

Abstract

Objective: To conduct a review of the investigational drug remdesivir and its therapeutic potential for treatment of COVID-19, in the form of a series of questions and answers. The purpose of the review is to narrow gaps in knowledge, clarify concepts, and to investigate research advancements for health care professionals. Data Sources: From June 2020 to August 2020, we conducted comprehensive searches of MEDLINE-PubMed, Scopus, and Google Scholar databases with no time limitations. Search terms were included that contained the terms "remdesivir," "COVID-19," "novel coronavirus" and "evidence," "therapy," "safety," "effectiveness," "efficacy," "clinical trial." Study Selection and Data Extraction: The sources of information include all publicly available data from previously published research reports. Reports must have at least one reference to remdesivir as a treatment modality for COVID-19 with no specified outcomes. Data Synthesis: Major research findings on the efficacy and safety of remdesivir are summarized in tabular format and presented in chronological order. Results of this review reveal remdesivir to be an effective therapy in specific clinical contexts; however, in several areas, available data are insufficient to support evidence-based guidance for remdesivir in the treatment of COVID-19. Conclusions: Clinical trials on remdesivir are ongoing, yet questions remain and further research is needed as to the selection of patients, effectiveness, and duration of treatment in the use of remdesivir for treatment of COVID-19.

Keywords: antibiotics; clinical pharmacy; disease management; dosage forms; dosing; drug information; drug safety; drug trials; mechanical; ventilators; viral infections.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. World Health Organization. Rolling updates on coronavirus disease (COVID-19). Updated July 31, 2020. Accessed September 21, 2020 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-a...
    1. Patel A, Jernigan DB; 2019-nCoV CDC Response Team. Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak—United States, December 31, 2019–February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:140-146. Accessed September 21, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6905e1.htm - PMC - PubMed
    1. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929-936. doi:10.1056/NEJMoa2001191 - DOI - PMC - PubMed
    1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Published May 2020. Accessed September 21, 2020 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technica...
    1. World Health Organization. WHO best practices for naming of new human infectious diseases. Published 2015. Accessed September 21, 2020 https://www.who.int/topics/infectious_diseases/naming-new-diseases/en/